News

Ligand’s Icagen and GSK enter global collaboration and license agreement to target neurological disorders

BY      |     December 22, 2020

Ligand, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, announced a new collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK).

This collaboration will utilize Icagen Technology Platform (which is focused primarily on ion channel and transporter novel drug discovery) to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.

Ligand will be responsible for most preclinical activities up to lead optimization, whilst GSK will lead further development and commercialization of any drug candidates identified through the collaboration.

Under the terms of the collaboration and license agreement, Ligand will receive a $7 million upfront payment and will be eligible for up to $154.5 million in milestone payments.

Read the press release here.

Read more about Ligand Pharmaceuticals here.

Read more about GSK here.



Photo by Andrea Piacquadio from Pexels


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.